University of Iowa Health Care
Welcome,         Profile    Billing    Logout  
 43 Trials 
58 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Haas, David
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
NCT05033743: Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

Completed
2/3
24
US
Secnidazole 2 GM Oral Granules
Indiana University, Lupin Pharmaceuticals, Inc.
Recurrent Bacterial Vaginosis
10/22
10/22
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
Hull, Andrew D
NCT01429389: Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Recruiting
N/A
2000
Canada, US
Sequenom, Inc.
Down Syndrome, Fetal Aneuploidy
12/25
03/26
Tumlin, James A
ADAPT, NCT05535920: A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

Completed
4
88
US
LOKELMA 5 GM Powder for Oral Suspension
NephroNet, Inc., AstraZeneca
Hyperkalemia
04/24
04/24
FACT, NCT05546047: A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

Active, not recruiting
4
34
US
Acthar Gel 80 UNT/ML Injectable Solution, Tacrolimus 1.0 mg
NephroNet, Inc., Mallinckrodt
Fibrillary Glomerulonephritis
10/23
10/24
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
DREAM-T2D, NCT04854512 / 2020-000763-23: Investigational Study of Delayed Release Metformin

Suspended
3
675
Europe, Canada, US, RoW
Metformin DR, ANJ900, MetDR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Anji Pharma
Diabetes Mellitus, Type 2
12/23
06/24
NCT03955445 / 2018-004253-24: Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

Recruiting
3
183
Europe, Canada, Japan, US, RoW
LNP023, iptacopan
Novartis Pharmaceuticals, Novartis Pharma AG
C3 Glomerulopathy, Idiopathic Immune-complex-membranoproliferative Glomerulonephritis
03/33
04/33
HUMAXX, NCT05908084: To Compare the Efficacy and Safety of the HAV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Recruiting
3
150
US
HAV, AVF
Humacyte, Inc.
End Stage Renal Disease (ESRD)
10/26
10/27
APPEAR-C3G, NCT04817618 / 2020-004589-21: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Hourglass Jul 2024 - Dec 2024 : Submission for the adult C3G
Hourglass Jul 2024 - Dec 2024 : Submission in US for the adult C3G
Recruiting
3
98
Europe, Canada, Japan, US, RoW
Placebo, iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
C3G
03/26
07/26
NCT06150924: Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects with Hypertension and Chronic Kidney Disease (CKD) with Albuminuria

Recruiting
2
60
US
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Mineralys Therapeutics Inc.
Chronic Kidney Disease
02/25
05/25
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
01/25
06/25
Lafayette, Richard
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases

Active, not recruiting
2
103
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627
Novartis Pharmaceuticals
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
07/24
07/26
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting
1/2
10
US
NRTX-1001, GABA-secreting interneurons
Neurona Therapeutics
Epilepsy, Temporal Lobe
07/26
07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26
TRIDENT, NCT02986984: Transformative Research in Diabetic Nephropathy

Recruiting
N/A
400
US
There is no intervention, There are no interventions
University of Pennsylvania, MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S
Diabetic Nephropathies, Diabetic Glomerulosclerosis
01/25
06/25
McNamara, Patrick
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
Bender, David P
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
VB-C-04, NCT06099418: Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Withdrawn
2
130
NA
VB10.16, Atezolizumab Injection [Tecentriq], Placebo
Nykode Therapeutics ASA, Roche Pharma AG, GOG Foundation
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
05/27
05/28
NXP800-101, NCT05226507: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer

Recruiting
1
61
Europe, US
NXP800
Nuvectis Pharma, Inc., European Network for Gynaecological Oncological Trial Groups, Gynecologic Oncology Group Foundation
Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
05/25
12/25
Truwit, Jonathon
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
Holmes, James F
NCT03564795: Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns

Terminated
N/A
14
US
KeraStat Gel, Silver Sulfadiazine, SSD
KeraNetics, LLC, Wake Forest University, United States Department of Defense
Partial-thickness Burn
03/23
03/23
Borowski, Kristi
NCT01429389: Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Recruiting
N/A
2000
Canada, US
Sequenom, Inc.
Down Syndrome, Fetal Aneuploidy
12/25
03/26
Seering, Melinda
NCT05486416: Safety and Efficacy of HSK3486 Compared to Propofol for Induction of General Anesthesia in Adults With Elective Surgery

Completed
3
466
Europe, US
HSK3486, Propofol, Diprivan
Haisco-USA Pharmaceuticals, Inc.
General Anesthesia
07/24
07/24
Paredes, Ana
APPEAR-C3G, NCT04817618 / 2020-004589-21: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Hourglass Jul 2024 - Dec 2024 : Submission for the adult C3G
Hourglass Jul 2024 - Dec 2024 : Submission in US for the adult C3G
Recruiting
3
98
Europe, Canada, Japan, US, RoW
Placebo, iptacopan, LNP023
Novartis Pharmaceuticals, Novartis Pharma AG
C3G
03/26
07/26
Fleener, Diedre
NCT01429389: Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Recruiting
N/A
2000
Canada, US
Sequenom, Inc.
Down Syndrome, Fetal Aneuploidy
12/25
03/26
Williams, Terry
MIRROR, NCT06074510: PYLARIFY® PET/CT or PET/MRI in Men with Favorable Intermediate Risk (FIR) Prostate Cancer

Recruiting
4
274
US
Piflufolastat F 18 Intravenous Solution [PYLARIFY], PYLARIFY, 18F-DCFPyL
Lantheus Medical Imaging
Prostate Cancer
11/26
11/26
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
NCT05156047: A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Completed
3
214
US
Open-label pitolisant, Double-blind placebo, Double-blind pitolisant
Harmony Biosciences, LLC
Idiopathic Hypersomnia
09/23
09/23
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
222
Canada, US
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/25
05/27
Borus, Linda
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
Pace, Benjamin
NCT06462820: SAINT for MDD in an Inpatient Setting Follow-on

Recruiting
2/3
100
US
Active SAINT Stimulation, Sham SAINT Stimulation
Magnus Medical
Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
12/25
02/26
NCT03693105: The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition

Recruiting
2/3
100
US
Active SAINT Stimulation, Sham SAINT Stimulation
Magnus Medical, National Institute of Mental Health (NIMH)
Major Depressive Disorder, Major Depressive Episode, Suicidal Ideation
12/25
02/26
Neki, Poonam
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Hourglass Feb 2024 - Dec 2024 : Topline data for adults with PV
Active, not recruiting
3
111
Canada, US
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
PharmaEssentia
Polycythemia Vera
12/24
07/25
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
Mundisev, Amy
NCT06107374: Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Recruiting
2
20
US
[18F]F-AraG
CellSight Technologies, Inc.
Advanced Non Small Cell Lung Cancer
12/25
03/26
NCT06084806: Test-retest Evaluation of [18F]F-AraG PET

Recruiting
2
10
US
[18F]F-ARAG PET
CellSight Technologies, Inc., University of Iowa
Non-small Cell Lung Cancer
10/25
10/25
NCT05759013: Pivotal Evaluation of Abdominal Neuromuscular Electrical Stimulation (VentFree) for Weaning from Mechanical Ventilation

Enrolling by invitation
N/A
272
Europe, US, RoW
Breath synchronized abdominal FES, VentFree Respiratory Muscle Stimulator, Sham breath synchronized abdominal FES
Liberate Medical, United States Department of Defense
Respiration, Artificial, Ventilators, Mechanical
12/25
03/26
Correia, Marcelo L
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
Buch, Vivek
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting
1/2
10
US
NRTX-1001, GABA-secreting interneurons
Neurona Therapeutics
Epilepsy, Temporal Lobe
07/26
07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26
NCT02844465: Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)

Completed
N/A
167
US
Visualase MRI-Guided Laser Ablation, Visualase System, Visualase procedure, Laser interstitial thermal therapy, Stereotactic laser ablation
MedtronicNeuro
Temporal Lobe Epilepsy
12/23
12/23
Badheka, Aditya
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Graber, Kevin
NCT06422923: A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Recruiting
1/2
10
US
NRTX-1001, GABA-secreting interneurons
Neurona Therapeutics
Epilepsy, Temporal Lobe
07/26
07/40
MTLE, NCT05135091: FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Recruiting
1/2
40
US
NRTX-1001, GABA-secreting interneurons, Sham Comparator
Neurona Therapeutics, California Institute for Regenerative Medicine (CIRM)
Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
05/25
05/26
Chegondi, Madhuradhar
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Hand, Lauren
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
PRESERVE-004, NCT05446298: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting
2
58
US
ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody made by OncoC4, Inc., Pembrolizumab, MK3475, Keytruda
OncoC4, Inc., Merck Sharp & Dohme LLC, GOG Foundation
Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
06/25
06/26
Landgrebe, Jessica
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
Clinic, UCI Alpha
NCT06169176: RAPA-501 Therapy for ALS Expanded Access Protocol

Available
2/3
40
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
 
 
LION-CS101, NCT05230459: A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Recruiting
1/2
10
US
AB-1003 dose level 1, AB-1003 dose level 2, Placebo
Asklepios Biopharmaceutical, Inc.
Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein
12/28
12/28
ENVISION, NCT06460844: Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa Patients

Recruiting
1
9
US
RTx-015
Ray Therapeutics, Inc.
Retinitis Pigmentosa
05/26
05/26
Buse, Emersosn
No trials found
Buse, Emerson
No trials found
Kochuyt, Ashley S
No trials found
Rubin, Yair
No trials found

Download Options